WO2017163268A3 - Forme d'administration pharmaceutique du divalproex à libération prolongée - Google Patents

Forme d'administration pharmaceutique du divalproex à libération prolongée Download PDF

Info

Publication number
WO2017163268A3
WO2017163268A3 PCT/IN2017/050107 IN2017050107W WO2017163268A3 WO 2017163268 A3 WO2017163268 A3 WO 2017163268A3 IN 2017050107 W IN2017050107 W IN 2017050107W WO 2017163268 A3 WO2017163268 A3 WO 2017163268A3
Authority
WO
WIPO (PCT)
Prior art keywords
divalproex
dosage form
sustained release
pharmaceutical dosage
release pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2017/050107
Other languages
English (en)
Other versions
WO2017163268A2 (fr
Inventor
Vishal SUHAGIYA
T Nathamani
Amol Kulkarni
Shirish Kulkarni
Rajamannar Thennati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of WO2017163268A2 publication Critical patent/WO2017163268A2/fr
Publication of WO2017163268A3 publication Critical patent/WO2017163268A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une forme d'administration pharmaceutique à libération prolongée comprenant du divalproex ou son sel et un polymère de régulation du taux, où lorsqu'une ou plusieurs unités de la forme d'administration pharmaceutique à libération prolongée comprenant une dose quotidienne totale réduite de divalproex ou de son sel, est/sont administrées une fois par jour, des taux de divalproex thérapeutiquement efficaces pour traiter les épisodes mixtes ou maniaques aigus associés à des troubles bipolaires avec ou sans caractéristiques psychotiques, crises partielles complexes et crises d'absence simples et complexes ou migraine sont obtenues.
PCT/IN2017/050107 2016-03-23 2017-03-23 Forme d'administration pharmaceutique du divalproex à libération prolongée Ceased WO2017163268A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621010254 2016-03-23
IN201621010254 2016-03-23

Publications (2)

Publication Number Publication Date
WO2017163268A2 WO2017163268A2 (fr) 2017-09-28
WO2017163268A3 true WO2017163268A3 (fr) 2018-01-11

Family

ID=59899150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2017/050107 Ceased WO2017163268A2 (fr) 2016-03-23 2017-03-23 Forme d'administration pharmaceutique du divalproex à libération prolongée

Country Status (1)

Country Link
WO (1) WO2017163268A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US20010005512A1 (en) * 1998-12-18 2001-06-28 Anderson William J. Controlled release formulation of divalproex sodium
WO2003103635A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formulation de divalproex de sodium a liberation prolongee
WO2008032208A2 (fr) * 2006-09-11 2008-03-20 Aurobindo Pharma Limited Formulation à libération prolongée d'un agent antiépileptique
WO2009008004A2 (fr) * 2007-05-23 2009-01-15 Sun Pharmaceutical Industries Limited Formulations à libération prolongée de divalproex de sodium

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
US20010005512A1 (en) * 1998-12-18 2001-06-28 Anderson William J. Controlled release formulation of divalproex sodium
WO2003103635A1 (fr) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Formulation de divalproex de sodium a liberation prolongee
WO2008032208A2 (fr) * 2006-09-11 2008-03-20 Aurobindo Pharma Limited Formulation à libération prolongée d'un agent antiépileptique
WO2009008004A2 (fr) * 2007-05-23 2009-01-15 Sun Pharmaceutical Industries Limited Formulations à libération prolongée de divalproex de sodium

Also Published As

Publication number Publication date
WO2017163268A2 (fr) 2017-09-28

Similar Documents

Publication Publication Date Title
EP4272818A3 (fr) Agent thrombolytique pour le traitement de la thrombo-embolie
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
WO2016131067A3 (fr) Compositions pharmaceutiques contenant du méloxicam
EP4512394A3 (fr) Formes galéniques et leur utilisation
WO2015121348A3 (fr) Composition pharmaceutique comprenant des érythrocytes encapsulant une enzyme dépendante du plp et son cofacteur
WO2015160975A3 (fr) Polythérapies
EP4650370A3 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant un antagoniste de l'il-31 comme principe actif
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2016055797A3 (fr) Composés et compositions pour le traitement ou la prévention d'affections pathologiques associées à l'excès de dépôt de fibrine et/ou à la formation de thrombus
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2016191458A3 (fr) Compositions pharmaceutiques ayant un effet sur l'état d'oxydoréduction mitochondriale et méthodes de traitement associées
WO2017060771A3 (fr) Polythérapies pour le traitement du cancer
CA3010981A1 (fr) Nanoparticules therapeutiques pour le traitement du neuroblastome et d'autres cancers
MX2018011799A (es) Formas de dosificacion de liberacion prolongada disuasivas de abuso.
CA3010568A1 (fr) Supports nanofibreux oromumuqueux pour traitement therapeutique
MX380070B (es) Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
TN2019000063A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
EP4461361A3 (fr) Utilisation d'une composition de vitamine dans la préparation d'un médicament pour prévenir, traiter ou retarder la maladie d'alzheimer
EP4474012A3 (fr) Mini-comprimés de mélatonine et leur procédé de fabrication
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
WO2017013490A3 (fr) Combinaisons thérapeutiques de paclitaxel et d'un inhibiteur de p-gp à usage oral pour le traitement du cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17769578

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17769578

Country of ref document: EP

Kind code of ref document: A2